Mirabegron

Mirabegron is a small-molecule beta-3 adrenergic receptor agonist developed by Astellas Pharma and marketed under the brand names Myrbetriq in the United States and Betmiga in Europe. It received US Food and Drug Administration approval in 2012 as a treatment for overactive bladder, becoming the first drug of its class to reach the market for that indication ^[1]. Chemically an acetanilide and thiazole derivative, it was designed to activate the beta-3 receptor subtype that predominates in the bladder wall ^[1].

In its approved role, mirabegron acts during the storage phase of the bladder cycle: activating beta-3 receptors on the detrusor smooth muscle promotes relaxation, which increases bladder capacity and reduces urgency and incontinence without the dry mouth and constipation typical of the older anticholinergic drugs ^[1]. Randomized comparisons and network meta-analyses place its efficacy alongside other bladder agents, with a tolerability profile that is generally favorable apart from a modest cardiovascular signal ^[6].

What has carried its reputation beyond urology is metabolism. Because beta-3 receptors also govern thermogenesis in brown adipose tissue and lipolysis in white fat, researchers have tested mirabegron as a tool to raise energy expenditure and improve metabolic health ^[2][3]. Human imaging studies have shown that it can activate brown fat and lift resting metabolic rate, and longer treatment has been associated with improvements in HDL cholesterol, insulin sensitivity, and the beneficial hormone adiponectin ^[2][3].

The picture is nuanced, however. Detailed physiology work indicates that human brown adipocyte thermogenesis is largely driven by the beta-2 rather than the beta-3 receptor, and that mirabegron reliably stimulates brown fat only at its maximal approved dose, where it begins to engage other adrenergic receptors ^[4]. Regulatory status is therefore clear-cut for bladder use and investigational for metabolism; it is supplied as extended-release oral tablets ^[1].

Mirabegron is a beta-3 adrenergic agonist that can raise blood pressure and heart rate, so blood pressure should be monitored and it is not recommended in people with severe uncontrolled hypertension. It may cause urinary retention, particularly with bladder outlet obstruction or when combined with antimuscarinic drugs, and rare cases of angioedema have been reported. It also inhibits CYP2D6, raising levels of some co-administered medicines such as certain beta-blockers and antidepressants.

Mirabegron is metabolized primarily by CYP3A4 with a minor CYP2D6 pathway; strong CYP3A4 inhibitors increase its plasma concentrations ^[15]. Ketoconazole increased mirabegron maximum concentration by 45% and area-under-curve by 81%, a pharmacokinetic effect where the CYP3A4 inhibitor reduces mirabegron clearance. Mirabegron itself acts as a moderate CYP2D6 inhibitor and increases systemic exposure of CYP2D6 substrates; co-administration with clozapine caused clinically significant elevations in clozapine levels that precipitated falls and sedation in an elderly patient ^[16].

These are pharmacokinetic interactions in which inhibitors of mirabegron's metabolic pathways decrease its clearance. Not documented; the specific effect of paroxetine on mirabegron, mirabegron's effects on CYP3A4 substrates other than index cases mentioned, and its interaction with other CYP2D6 substrates beyond those studied.

Checking a whole stack? Run it through interactions + stacks.

Mirabegron was developed by Astellas Pharma as the first beta-3 adrenergic receptor agonist to reach the market, receiving United States Food and Drug Administration approval in 2012 under the brand name Myrbetriq for overactive bladder. Its approval followed a long pharmaceutical search for a selective beta-3 agonist that could relax the bladder without the anticholinergic side effects of older therapies.

Because beta-3 receptors are the principal adrenergic activators of brown adipose tissue, the drug quickly attracted metabolic-research interest, and in 2015 a landmark Cell Metabolism study showed that a single 200 mg dose activated human brown fat and raised resting metabolic rate. Subsequent work refined the picture, demonstrating in 2020 that human brown-fat thermogenesis is driven chiefly by beta-2 receptors and that mirabegron recruits brown fat clearly only at its highest approved dose.

Mirabegron is well regarded as a clinically validated bladder therapy with an established safety record, and it has become a favorite tool of metabolic researchers because it offers a rare pharmacological handle on human brown adipose tissue. The 2015 demonstration that it raised resting energy expenditure by about 13 percent generated considerable excitement about brown fat as a target for obesity and diabetes. Later studies tempered that enthusiasm by clarifying that its brown-fat effect at high doses partly reflects off-target beta-2 and beta-1 activation, which also raises heart rate and blood pressure. The compound is therefore discussed as a genuine proof of concept rather than a finished metabolic drug. Its dual identity, a routine urology medicine and a frontier research probe, keeps it a subject of active investigation.